Treating pulmonary disorders with gaseous agent causing repletion of GSNO

Abstract

Pulmonary disorders in which the GSNO pool or glutathione pool in the lung is depleted and where reactive oxygen species in lung are increased, are treated by delivering into the lung as a gas, agent causing repletion or increase of the GSNO pool or protection against toxicity and does so independently of reaction with oxygen. Agents include ethyl nitrite, NOCl, NOBr, NOF, NOCN, N2O3, HNO, and H2S. Optionally, N-acetylcysteine, ascorbate, H2S or HNO is administered in addition to other GSNO repleting agent to potentiate the effect of said agent.

Description

CROSS-REFERENCE TO RELATED APPLICATION [0001] This application is a continuation of U.S. patent application Ser. No. 09 / 782,077, filed Feb. 14, 2001, which is a continuation-in-part of U.S. patent application Ser. No. 09 / 390,215, filed on Sep. 8, 1999, now U.S. Pat. No. 6,314,956. The contents of these applications are each incorporated herein by reference in their entirety.TECHNICAL FIELD [0002] This invention relates to treating lung disorders by delivery of a gas into the lungs. BACKGROUND OF THE INVENTION [0003] Inhaled nitric oxide (NO) is used to treat elevated pulmonary pressures and pulmonary disorders associated with hypoxemia. This provides hypoxemia relieving and smooth muscle constriction relieving effects, but side effects include inflammation, airway hyperactivity, hemorrhage, and reaction with hemoglobin resulting in interference with its oxygen delivery function. In addition, this impairs renal function and even increases mortality in some subsets. The hypoxemia reli...

AI Technical Summary

Benefits of technology

[0006] This invention relies on the conception that for lung disorders associated with depletion of the S-nitrosoglutathione (GSNO) pool in lung or depletion of the glutathione pool in lung or increased production of reactive oxygen species in lung, treatment with inhaled gases to replete or increase the S-nitrosoglutathione pool and / or to react preferentially with glutathione to form other NO glutathione derivatives independently of reaction with oxygen, would provide the benefits of treatment using gas inhalation of matching ventilation to perfusion and suitability for administration by an anesthesiologist and the benefits of treatment using inhaled NO of hypoxemia relieving effect and / or smooth muscle relieving effect, and additionally would provide antimicrobial effect and anti-inflammatory activity, and these activities would be provided with less toxicities than previous alternative therapies. The totality of the benefits is important, for example, not only in respect to treatment of asthma, for example, which is associated with smooth muscle constriction in lung and can be associated with hypoxemia, and where lung infection can be a secondary problem, but also in respect to cystic fibrosis where airway lining can be impaired to the extent that relaxing of the airway is not therapeutic, but where antimicrobial effect is important to treat infection associated with cystic fibrosis or where increased GSNO or glutathione (GSH) reactive compounds can upregulate the cystic fibrosis transmembrane regulator. In respect to treating cystic fibrosis, inhaled gaseous GSNO repleting or increase causing agents also function better than inhaled NO because they cause increase in cystic fibrosis transmembrane regulator and inhaled NO does not and / or are less toxic than NO.

[0013] The term “replete or increase the S-nitrosoglutathione pool” is used herein to mean preventing breakdown of GSNO, for example, by scavenging reactive oxygen species, or increasing levels of GSNO by molecules that generate either GSNO directly or GSNO like species which can be readily converted to GSNO including GSNO., GSNHOH or GSNO2. The obtaining of this result can be determined, for example, by chemiluminescence analysis of airway lining fluid or exhaled breath.

[0017] In another such case, ascorbate is administered to the patient in addition to the delivery into the lungs of the patient as a gas of the S-nitrosoglutathione pool repleting or increase causing agent, to mediate repletion or increase of the S-nitrosoglutathione pool and / or potentiate the effect of said S-nitrosoglutathione pool repleting or increase causing agent administered as gas. Administration of the ascorbate is in an amount effective to mediate repletion or increase of the S-nitrosothiol pool in the lung and / or protect from injury as measured by indices such as decreased H2O2 in expired breadth or decreased thiobarbituric acid derivatives in expired breath or decreased carbon monoxide in expired breath or decreased nitration in lung.

[0018] If desired, both N-acetylcysteine and ascorbate can be administered to a patient in addition to delivery into the lungs of the patient as a gas of the S-nitrosoglutathione pool repleting or increase causing agent, to mediate repleting or increase of the S-nitrosoglutathione pool and / or potentiate the effect of said S-nitrosoglutathione pool repleting or increase causing agent administered as a gas.

[0019] In another case H2S, and in still another case HNO or HNO donor compound, e.g., Angeli's salt or piloty acid, are given preferentially as gases, in the first case (H2S) to replete glutathione and / or decrease reactive oxygen species and / or potentiate the effect of any other S-nitrosoglutathione pool repleting or increase causing agent administered, and in the second case (HNO or HNO donor compound) to raise GSNO levels in the lung, in addition to delivery into the lungs as a gas of other S-nitrosoglutathione pool repleting or increase causing agent.

Problems solved by technology

While it is known to treat lung disorders by inhibiting reduction of GSNO by administering inhibitor of S-nitrosoglutathione reductase, also known as glutathione dependent formaldehyde dehydrogenase (U.S. application Ser. No. 09 / 757,610, filed Jan. 11, 2001), and by preventing and / or accommodating for S-nitrosothiol breakdown by administering certain treating agents (U.S. application Ser. No. 09 / 403,775, filed Nov. 4, 1999), these patent applications do not specifically disclose delivery into the lungs as a gas, an agent which causes repletion or increase of the GSNO pool, and they do not consider thiols and other anti-oxidants such as N-acetylcysteine, ascorbate and H2S which can increase the GSNO pool.

If a dilated blood vessel in lung is not juxtaposed to an air sac, oxygenation can be impaired by the dilation, and improved oxygen delivery to the air sac will not improve blood oxygenation.

This is explified in treatment by the administration of the vasorelaxant dobutamine, which, while dilating blood vessels in lung, impairs ventilation to perfusion matching.

Images